D. E. Shaw & Co., Inc. Passage Bio, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PASG
# of Institutions
47Shares Held
38.7MCall Options Held
7.7KPut Options Held
0-
Orbimed Advisors LLC San Diego, CA9.82MShares$6.48 Million0.16% of portfolio
-
Lynx1 Capital Management LP San Juan, PR8.43MShares$5.56 Million2.11% of portfolio
-
Vestal Point Capital, LP New York, NY6.1MShares$4.03 Million0.32% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY2.5MShares$1.65 Million1.8% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.46MShares$1.62 Million0.02% of portfolio
About Passage BIO, Inc.
- Ticker PASG
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,463,200
- Market Cap $35.9M
- Description
- Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...